SYNVISC®
Manufacturer: Sanofi Genzyme Active Substance(s): HYLAN GF…
What Is Synvisc® and Why Do Practitioners Prescribe It for Knee OA?
Synvisc® is a viscosupplement composed of hylan G-F 20, a cross-linked derivative of hyaluronan formulated to replicate the viscoelastic properties of healthy synovial fluid in the osteoarthritic knee joint [5]. It is administered via intra-articular injection and indicated for patients with knee osteoarthritis pain who have not achieved adequate symptom control through conservative management — including physical therapy, oral analgesics, and lifestyle modification [4][5].
The product’s sustained adoption in orthopedic, rheumatology, and sports medicine settings reflects both its clinical evidence base and its practical positioning as a non-surgical pain treatment option for patients delaying or seeking to avoid knee replacement surgery [2]. Practitioners managing knee OA treatment pathways who source from multiple injectable categories can also buy orthopedic injections through Medica Depot’s orthopedic category alongside Synvisc® to build a comprehensive viscosupplementation and injectable joint-care inventory.
Synvisc® Products — Comparing the Two Formulations
Synvisc® is available in two dosing configurations that share the same hylan G-F 20 active substance but differ in administration schedule and clinical workflow integration [5]. Consider these differences when looking to order Synvisc®.
The standard Synvisc® formulation is supplied at 16 mg/2 mL per syringe and administered as three weekly intra-articular injections over consecutive weeks [5]. This regimen suits practices in which structured follow-up visits are built into the treatment model — allowing clinicians to monitor patient response over the course and adjust supportive care as needed. The staged delivery provides an opportunity to reassess treatment response before completing the full series.
Synvisc-One® delivers 48 mg/6 mL of hylan G-F 20 in a single intra-articular injection for one knee [5]. Designed to reduce visit burden and support treatment completion in patients with scheduling or adherence constraints, it is often the preferred format in high-throughput clinical settings or where multi-visit compliance is a documented challenge. A randomized, multicentre, double-blind, placebo-controlled trial demonstrated that a single 6 mL intra-articular injection of hylan G-F 20 produced significant pain relief over 26 weeks, supporting its clinical equivalence to the multi-injection course [3].
For clinics stocking both, the dual-format portfolio means a single brand relationship covers practices with different patient populations and workflow models. This is a procurement efficiency that simplifies formula decisions without requiring clinical compromise on active substance. You can buy Synvisc® online, at Medica Depot, where we offer the most competitive prices. Contact us to order Synvisc® wholesale.
Sanofi and Genzyme — The Global Pharmaceutical Expertise Behind Synvisc®
The Synvisc® product line was developed by Genzyme, a biotechnology company that built the hylan G-F 20 platform and brought both Synvisc® and Synvisc-One® through regulatory approval across major markets [4][5]. Genzyme was acquired by Sanofi in 2011, integrating Synvisc® into one of the world’s largest pharmaceutical and medical device portfolios.
For procurement teams evaluating wholesale sources, Sanofi’s manufacturing infrastructure for Synvisc® supports validated production standards, regulatory traceability, and consistent, long-term global distribution [5]. The established global footprint means supply chain continuity is predictable — a relevant consideration for clinics that schedule Synvisc® injections as part of ongoing OA management programs and need reliable access to inventory across treatment cycles.
Synvisc® Injection Protocols — A Practical Clinical Reference
Both Synvisc® formulations are administered as intra-articular injections directly into the knee joint under aseptic conditions [5]. Where synovial effusion is present, aspiration before injection is typically performed to optimize product distribution within the joint space.
The standard Synvisc® course delivers one 2 mL injection per week for three consecutive weeks [5]. Synvisc-One® delivers the full course equivalent in a single 6 mL injection, with clinical evidence supporting its efficacy over a 26-week period [3][5]. Appropriate needle selection, sterile site preparation, and post-injection activity modification for 24–48 hours are standard procedural elements across both protocols [5].
For billing and documentation, practitioners typically reference CPT code 20610 (arthrocentesis, aspiration and/or injection of a major joint) alongside the applicable product J-code when submitting Synvisc® claims within US payer systems. Practitioners should verify current J-code assignments through payer documentation, as product-specific billing codes are subject to periodic update.
Synvisc® Global Market Presence and Distribution
Synvisc® is distributed across major international healthcare markets — the United States, Canada, the European Union, and Australia — supported by its long-standing regulatory approvals and established clinical adoption across orthopedic and rheumatology practice settings [4][5]. Its dual-format portfolio and recognized hylan G-F 20 platform make it a benchmark product in viscosupplementation formularies globally. Contact Medica Depot for more information about choosing a Synvisc® supplier.
For licensed practitioners managing multi-category injectable inventories, Medica Depot also allows them to buy hyaluronic acid dermal fillers alongside its orthopedic injectable range — a consolidated sourcing option for clinics treating both joint health and aesthetic indications from the same supplier relationship.
Medica Depot works with clients, as they buy Synvisc® wholesale, offering reliable procurement channels, with verified product sourcing and logistics built around clinical needs.
Regulatory Approvals — Is Synvisc® Cleared in Your Market?
Synvisc® received FDA Premarket Approval (PMA Number: P940015) as a Class III medical device for the treatment of knee osteoarthritis pain in patients who have not responded adequately to conservative therapy and simple analgesics [4]. Its Class III classification reflects the FDA’s regulatory scrutiny of intra-articular implants — PMA requires a more rigorous premarket review process than 510(k) clearance. Initial PMA approval was granted in 1997, with Synvisc-One® receiving its own PMA supplement through the same framework [4].
Equivalent regulatory approvals exist across key international markets: CE marking in the European Union, Health Canada authorization, and TGA listing in Australia [5]. These approvals collectively confirm Synvisc® as a clinically evaluated, market-authorized viscosupplement for the management of knee OA pain in each jurisdiction.
Hylan G-F 20 — The Cross-Linked Hyaluronan Technology Differentiating Synvisc®
Hylan G-F 20 is produced by cross-linking hyaluronan chains, creating a molecular structure with greater mechanical stability and a longer residence time in the joint space compared with non-cross-linked hyaluronic acid formulations [2][5]. This structural modification enhances the viscoelastic properties of the injected material, supporting joint lubrication and mechanical cushioning under the dynamic loads generated during weight-bearing activity [2].
In clinical comparisons, the molecular architecture of hylan G-F 20 is a frequent point of differentiation: its cross-linked structure distinguishes it from both non-cross-linked high-molecular-weight HA products and non-avian biofermentation-derived formulations [2][5]. The practical implication for clinicians is that hylan G-F 20’s extended joint residence supports sustained symptomatic relief in appropriately selected patients, which influences prescribing decisions when evaluating viscosupplementation options across a patient panel with varying OA severity and activity levels [1][2].
Which Patients Are Candidates for Synvisc® Treatment?
Synvisc® is indicated for patients with symptomatic knee osteoarthritis who continue to experience pain, stiffness, or reduced mobility despite conservative management [4][5]. Viscosupplementation consensus guidance supports individualized patient selection — response varies meaningfully with patient characteristics, including OA severity, age, BMI, and prior treatment history, and appropriate candidate identification is a key determinant of outcome [1].
Before clinicians buy Synvisc®, they should carefully consider the patient profile:
Typical candidates have not achieved adequate relief from physical therapy, oral analgesics, or lifestyle modification, and may be seeking to delay knee replacement surgery or reduce reliance on systemic medications through localized intra-articular therapy [1][4]. Contraindications include confirmed hypersensitivity to hyaluronan products or avian-derived proteins — clinically relevant given Synvisc®’s chicken-comb origin — as well as active infections at or near the injection site and confirmed joint infections [5]. Pre-procedure patient screening for avian protein sensitivity is standard in Synvisc® treatment protocols; practitioners should document screening findings in the patient record before proceeding [5]. Clinics can order Synvisc® through Medica Depot.
Two Reasons Why Practitioners Prefer to Order Synvisc® Online Through Medica Depot
Synvisc® has one of the most extensive long-term evidence bases in viscosupplementation — including systematic reviews, network meta-analyses, and randomized controlled trial data evaluating efficacy, safety, and comparisons with corticosteroid injections in knee OA [2][3]. This depth of evidence provides both practitioners and patients with a reliable framework for setting treatment expectations and supports reimbursement authorization in payer environments where documented clinical evidence is a coverage requirement.
Furthermore, Synvisc-One®’s single-injection option delivers the equivalent active-substance dose to a three-injection course in a single clinic visit, reducing appointment burden without clinical compromise [3][5]. For practices managing a mix of compliant and adherence-challenged patient populations, maintaining access to both formats under one brand means the clinical decision between staged and consolidated treatment stays in the practitioner’s hands rather than being dictated by formulary limitations.
Medica Depot stocks the complete Synvisc® range, and practitioners sourcing across multiple categories can also buy dermal fillers, which is ideal for clinics running aesthetic programs alongside orthopedic care. Contact Medica Depot to buy Synvisc® products.
Synvisc® vs ORTHOVISC®, EUFLEXXA®, and MONOVISC®
Synvisc® vs ORTHOVISC®
Synvisc® uses hylan G-F 20 — a cross-linked hyaluronan derivative with extended joint residence time — while ORTHOVISC® is a non-cross-linked, ultra-high-molecular-weight hyaluronic acid product [2][5]. The structural difference means the two products have distinct viscoelastic profiles in the joint space: Synvisc®’s cross-linking provides mechanical durability under dynamic load, while ORTHOVISC®’s ultra-high molecular weight delivers viscosity through chain length rather than chemical modification.
In procurement planning, practices that intend to buy ORTHOVISC® or maintain multiple viscosupplementation options may still retain Synvisc® due to its long clinical track record and dual-formulation flexibility.
Synvisc® vs EUFLEXXA®
The defining clinical distinction between Synvisc® and EUFLEXXA® is source material. Synvisc® is derived from avian hyaluronan — specifically chicken comb — and cross-linked to form hylan G-F 20, while EUFLEXXA® uses non-avian sodium hyaluronate produced via bacterial biofermentation [5]. For patients with documented or suspected sensitivity to avian proteins, feathers, or eggs, EUFLEXXA® removes the avian-source contraindication that applies to Synvisc® and becomes the clinically appropriate alternative for that subset [1][5]. Practitioners managing patient populations with avian sensitivity profiles can buy EUFLEXXA® for direct inclusion in those protocols.
Synvisc® vs MONOVISC®
Synvisc® and MONOVISC® each offer a single-injection administration format — Synvisc-One® on the Synvisc® side — but the two differ in their active substances and molecular architectures [2][5]. Synvisc-One® uses cross-linked hylan G-F 20; MONOVISC® uses a cross-linked hyaluronic acid formulation with its own molecular weight and rheological profile. The practical comparison between them is less about administration convenience — both achieve a single-visit treatment — and more about formulation familiarity, prior patient response history, and payer coverage specifics [1].
For procurement teams, the decision to buy MONOVISC® versus stocking Synvisc® often depends on balancing injection-scheduling efficiency with brand continuity and clinician preferences across knee osteoarthritis treatment pathways.
Synvisc® Safety and Tolerability — What Practitioners and Patients Should Know
Adverse events associated with Synvisc® are predominantly localized to the injection site and consistent with those documented for intra-articular hyaluronic acid products as a class [2][5]. Common reactions include transient pain, swelling, warmth, stiffness, and joint effusion following administration — effects that are generally mild and self-limiting, resolving without significant intervention in most patients [2][5].
A more serious but less common reaction is the acute local joint reaction, sometimes referred to as a pseudoseptic reaction, characterized by pronounced joint inflammation, warmth, and swelling that may occur within 24–72 hours of injection [5]. This reaction requires clinical differentiation from infectious arthritis and appropriate management; its occurrence is the basis for post-injection monitoring guidance included in Synvisc® prescribing information [5].
When comparing Synvisc® with corticosteroid injections as alternative intra-articular treatments, systematic review evidence indicates that both approaches have distinct adverse-event profiles, with the local reaction risk pattern for hylan G-F 20 generally favoring its use in patients for whom repeated steroid exposure is a clinical concern [2].
Hypertension and systemic weight changes are not recognized adverse effects of Synvisc® — the product acts locally within the joint space and has no established systemic mechanism for those outcomes [5].
Contraindications include confirmed hypersensitivity to hyaluronan products or avian-derived proteins, active skin disease or infection at the proposed injection site, and joint infections [5]. Pre-treatment aspiration of joint effusion where present, strict aseptic technique, and post-procedure patient monitoring are standard safety components of the Synvisc® injection protocol [5].
Buy Synvisc® Wholesale – How Procurement Works
For licensed professionals interested to buy Synvisc® online at wholesale prices, procurement through Medica Depot involves verifying product availability, confirming documentation requirements for professional purchasing, and aligning order quantities with clinic treatment volumes and scheduling cycles.
Medica Depot’s team can provide guidance on current availability of Synvisc® and Synvisc-One®, group purchasing options, and the ordering workflow designed specifically for licensed healthcare environments. Practitioners evaluating wholesale access for viscosupplementation inventory — whether for a single-location orthopedic practice or a multi-site rheumatology group — can contact the team directly for pricing details, LOT verification documentation, and fulfillment timelines suited to their clinical supply requirements.
Frequently Asked Questions
Who may be considered for Synvisc® treatment?
Synvisc® may be considered for patients with knee osteoarthritis who continue to experience pain despite conservative measures such as physical therapy, analgesics, or lifestyle modification [4][5]. Suitability should be assessed individually based on symptom severity, treatment history, allergy profile, and overall joint condition.
When might Synvisc-One® be preferred over the three-dose Synvisc® series?
Synvisc-One® may be useful when reducing the number of clinic visits is an important consideration. It delivers the full hylan G-F 20 treatment dose in a single 6 mL injection, whereas standard Synvisc® is administered as three weekly 2 mL injections [5].
Why does Synvisc® require avian allergy screening?
Synvisc® is manufactured from chicken comb-derived hyaluronan. Practitioners should therefore review relevant avian, feather, egg, or poultry sensitivities and follow the current product contraindications before treatment [5].
What should patients expect after a Synvisc® injection?
Temporary pain, swelling, warmth, stiffness, or joint fullness may occur after treatment [2][5]. Patients are commonly advised to limit strenuous or prolonged weight-bearing activity for approximately 24–48 hours and follow any individualized post-injection instructions from their clinician.
How should clinicians evaluate whether Synvisc® is providing benefit?
Treatment response can be assessed through changes in knee pain, walking tolerance, mobility, daily function, and patient-reported activity limitations. Because response varies between patients, follow-up assessment is more useful than assuming a fixed level or duration of benefit [1][2].
Can Synvisc® treatment be repeated if symptoms return?
Repeat treatment cycles may be considered when osteoarthritis symptoms recur and the patient previously experienced meaningful benefit. Timing should be based on clinical reassessment, current product guidance, treatment history, and any payer-specific requirements.
What is a pseudoseptic reaction after Synvisc®?
A pseudoseptic reaction is an acute inflammatory joint response that can resemble septic arthritis, with significant pain, swelling, or effusion after injection [5]. Although uncommon, it requires prompt clinical assessment so infection and other causes of acute joint inflammation can be ruled out.
Where can licensed practitioners order Synvisc® wholesale?
Licensed medical professionals can contact Medica Depot for information on Synvisc® wholesale pricing, Synvisc® and Synvisc-One® availability, LOT documentation, and professional procurement support. Clinics may also review group-order options and expected treatment volume when planning viscosupplement inventory in contact with a dedicated account manager from our team. We make it easy to order Synvisc® online, with fast license verification within 24 hours. Our shipping service guarantees delivery within 14 days, and clients can contact our customer team to track their order, or ask for a replacement or refund in case anything goes wrong, or they are not satisfied. Before you purchase Synvisc®, confirm the required format and quantities for your clinic.
Disclaimer
The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.
Citations and Resources
[1] Conrozier T, Raman R, Diraçoglu D, et al. EUROVISCO Consensus Guidelines for the Use of Hyaluronic Acid Viscosupplementation in Knee Osteoarthritis Based on Patient Characteristics. Cartilage. 2024. https://pubmed.ncbi.nlm.nih.gov/39564753/
[2] Chevalier X, Sheehan B, Whittington C, et al. Efficacy and Safety of Hylan G-F 20 Versus Intra-Articular Corticosteroids in People with Knee Osteoarthritis: A Systematic Review and Network Meta-Analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2020.https://pubmed.ncbi.nlm.nih.gov/33281462/
[3] Chevalier X, Jerosch J, Goupille P, et al. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial. Annals of the Rheumatic Diseases. 2010. https://pubmed.ncbi.nlm.nih.gov/19304567/
[4] U.S. Food and Drug Administration. Premarket Approval (PMA) — P940015. Updated 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P940015
[5] Sanofi. SYNVISC® Hylan G-F 20 Prescribing Information. https://products.sanofi.us/synvisc/synvisc.html
Written by the Medica Depot Editorial Staff
This content was prepared and reviewed under our editorial guidelines , which govern how we source, verify, and update clinical and product information. Every claim is checked against peer-reviewed research, manufacturer documentation, or regulatory guidance before publication.
Choosing the right products starts with confidence in their authenticity. At Medica Depot, we prioritize genuine branded products, reliable sourcing, and quality you can trust. Explore our standards and learn more about how we ensure product authenticity.